Previous close | 1.8300 |
Open | 2.4300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 125.00 |
Expiry date | 2024-08-16 |
Day's range | 1.6500 - 2.6000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceutical company awaits the Centers for Disease Control's (CDC) recommendation. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...